EGFR and lung adenocarcinoma: Expression of either RIT1M90I or KRASG12V in PC9 EGFR-mutant lung adenocarcinoma cells renders them resistant to the EGFR inhibitors erlotinib (Fig. 1b) or osimertinib (Fig. 1c), conferring an almost 1000-fold decrease in drug sensitivity.